Literature DB >> 22153963

[Cochleovestibular dysfunction in patients with diabetes mellitus, hypertension and dyslipidemia].

María Estela Chávez-Delgado1, Irma Vázquez-Granados, Manuel Rosales-Cortés, Víctor Velasco-Rodríguez.   

Abstract

INTRODUCTION AND
OBJECTIVE: Polygenic or multifactorial inheritance of chronic disorders (MICD) contribute to irreversible cochleovestibular impairment. Our aim was to determine the type and degree of cochleovestibular dysfunction (CVD) in patients with MICD.
METHODS: Cross-sectional. We studied 385 patients with type 2 diabetes mellitus, systemic arterial hypertension and dyslipidemia who were referred to Otorhinolaryngology Unit with hearing and vestibular symptoms. The auditory function was evaluated using conventional tonal audiometry and the vestibular function by electronystagmography. Duration of the disease and number of comorbidities, hearing thresholds at 125-8000 Hz pure tones, speech audiometry, oculomotor evaluation and thermal caloric tests were also analysed.
RESULTS: A total of 66.7% (95% CI, 61.8-73.4) of patients had 1 comorbidity; 27.7% (95% CI, 23.3-32.5) had 2 and 5.4% (95% CI, 3.4-8.2) had systemic arterial hypertension, diabetes mellitus and dyslipidemia. The mean age was 62 years (SD 12.9) and 57.1% were women. The majority showed obesity, physical inactivity and smoking (77.4%; 95% CI, 72.8-81.4). Cochlear dysfunction was more common than CVD (98.9%; 95% CI, 97.3-99.7 versus 36.1%; 95%CI, 31.2-41.1; P=.001). However, the presence of CVD was significant in patients over 60 years (χ(2)(tend), P≤.001, odds ratio: 6.43) and with MICD ≥11 years old (χ(2)(tend), P≤.001, odds ratio: 4.57).
CONCLUSIONS: Cochlear dysfunction occurs in patients with MICD and the impact is greater than that of vestibular dysfunction. However, the age factor, duration and number of MICDs contribute to CVD. It is necessary to act on the MICDs and lifestyles to improve CVD. Copyright Â
© 2011 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22153963     DOI: 10.1016/j.otorri.2011.09.001

Source DB:  PubMed          Journal:  Acta Otorrinolaringol Esp        ISSN: 0001-6519


  7 in total

1.  The effect of thyroid autoantibody positivity on the functions of internal ear.

Authors:  Akif Gunes; Mehmet Fatih Karakus; Tugba Akin Telli; Nurcan Akbas Gunes; Murad Mutlu
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-08-18       Impact factor: 2.503

2.  Evaluation of hearing functions in patients with euthyroid Hashimoto's thyroiditis.

Authors:  Ayse Arduc; Serhat Isık; Serpil Allusoglu; Ayse Iriz; Bercem Aycicek Dogan; Celil Gocer; Mazhar Muslim Tuna; Dilek Berker; Serdar Guler
Journal:  Endocrine       Date:  2015-05-12       Impact factor: 3.633

3.  Retrospective data suggests that the higher prevalence of benign paroxysmal positional vertigo in individuals with type 2 diabetes is mediated by hypertension.

Authors:  Linda J D'Silva; Hinrich Staecker; James Lin; Kevin J Sykes; Milind A Phadnis; Tamara M McMahon; Dan Connolly; Carla H Sabus; Susan L Whitney; Patricia M Kluding
Journal:  J Vestib Res       Date:  2016       Impact factor: 2.435

Review 4.  Impact of Diabetic Complications on Balance and Falls: Contribution of the Vestibular System.

Authors:  Linda J D'Silva; James Lin; Hinrich Staecker; Susan L Whitney; Patricia M Kluding
Journal:  Phys Ther       Date:  2015-08-06

Review 5.  Tinnitus and arterial hypertension: a systematic review.

Authors:  Ricardo Rodrigues Figueiredo; Andréia Aparecida de Azevedo; Norma de Oliveira Penido
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-09-05       Impact factor: 2.503

6.  Seasonality and Cardio-Cerebrovascular Risk Factors for Benign Paroxysmal Positional Vertigo.

Authors:  Zhentang Cao; Xingquan Zhao; Yi Ju; Meimei Chen; Yan Wang
Journal:  Front Neurol       Date:  2020-04-09       Impact factor: 4.003

Review 7.  A Systematic Review and Meta-Analysis on the Association between Hypertension and Tinnitus.

Authors:  Pan Yang; Wenjun Ma; Yiqing Zheng; Haidi Yang; Hualiang Lin
Journal:  Int J Hypertens       Date:  2015-12-31       Impact factor: 2.420

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.